Clin2
NCT06466525Possibly a fitRecruiting

Testing LBT-3627 for safety in healthy adults and people with Parkinson's

Parkinson Disease

Part of Brain & nervous system clinical trials.

This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
64 people
Ages
30 years to 89 years
Study type
Interventional

Who can take part

  • You are between 30 and 89 years old.
  • Your body mass index (BMI) is between 18 and 32.
  • You do not have significant heart, liver, kidney, or other major health problems.
  • You are not taking certain medications, like steroids or immune-suppressing drugs, within the required time before the study.
  • If you have Parkinson's disease, you must have been diagnosed within the last 6 months to 11 years and be in stages 1 to 3.
  • If you take levodopa for Parkinson's, you must be on a stable dose and be able to skip it for at least 12 hours during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06732180Recruiting· Phase 1
Testing a new drug (GT-02287) for Parkinson's disease

This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.

Darlinghurst, New South Wales
NCT07280299Not yet recruiting· Phase 2
Study of a new medicine for early Parkinson's disease

This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.

NCT06997484Recruiting· Phase 1
Testing safety of HL-400 in healthy adults

This study tests a new drug called HL-400 for the first time in people. It checks how safe the drug is and how the body handles it, to see if it could be developed for future patients.

Baltimore, Maryland
NCT06976268Recruiting· Phase 2/Phase 3
Testing BHV-8000 for early Parkinson's disease

This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.

Birmingham, Alabama
NCT06809400Recruiting· Phase 1
Study of LY4006896 for Parkinson's disease

This study tests an investigational drug called LY4006896 in healthy people and in people with Parkinson's disease. It aims to see if the drug is safe and how it affects the body, which may help in developing a new treatment for Parkinson's.

Los Alamitos, California
NCT07781644Not yet recruiting· Phase 1/Phase 2
Testing a new drug for early Parkinson's disease

This trial tests an experimental drug called RO7568282 to see if it is safe and can help with early Parkinson's disease symptoms. It is for people who have been taking a stable dose of levodopa alone for at least two months.

Hear when a new Parkinson Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.